sthrn labs is launching soon. Browse the catalog, review our COAs, and inquire to order.
GLP-2T
Tirzepatide is a dual agonist peptide targeting GLP-1 and GIP receptors. It is studied for its potential effects on metabolic regulation, glucose control, and body composition in preclinical research models. For research use only.
Compound information
What is GLP-2T?
Stability information
Research highlights
Dual incretin agonism
Research on simultaneous GIP and GLP-1 receptor activation and combined signaling dynamics.
Glycemic regulation
Studies exploring glucose-dependent insulin secretion and HbA1c response.
Appetite and satiety signaling
Investigating central pathways governing food intake and energy balance.
Gastric emptying modulation
Exploration of slowed gastric transit and its metabolic downstream effects.
Sources & references
Tirzepatide once weekly for the treatment of obesity
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity
All citations link directly to primary literature. sthrn labs does not reproduce, excerpt, or summarize article content.
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
